EBRC has been active in clinical trials for over 13 years and continues to be a site that has been involved in landmark studies involving the treatment of age-related macular degeneration, diabetic retinopathy and retinal vein occlusions. EBRC continues to dedicate our time and efforts toward promoting the advancement in retinal research and improving our surgical and medical care for each of our patients.

Our research team carefully evaluates each research study and selects well-designed and safe clinical studies that will not only benefit each of our participating patients, but also aid in the future discovery of treatment for retinal diseases.

Clinical Trials

Active Clinical Trials


Completed Clinical Trials

Age-Related Macular Degeneration
  • RE-VIEW: Phase IV, Aflibercept injections in subjects for the treatment of neovascular age-related macular degeneration.
  • HARBOR: Phase III, Ranibizumab injections in subjects with subfoveal
    neovascular age related macular degeneration.
  • DENALI: Phase IIIB, Verteporfin photodynamic therapy administered in
    conjunction with ranibizumab in subjects with choroidal neovascularization secondary to age-related macular degeneration.
  • VIEW 1: Phase III, VEGF-Trap injections in subjects with neovascular age related macular degeneration.
  • SAILOR: Phase IIIb, Ranibizumab injections in subjects with macular edema secondary to age-related macular degeneration.
  • PIER: Phase IIIb, Ranibizumab injections with subfoveal choroidal
    neovascularization with or without classic CNV secondary to age-related macular degeneration.
Diabetic Macular Edema
  • VISTA: Phase III, VEGF-Trap injections/laser in subjects for the treatment of diabetic macular edema.
  • IDEAL: Phase II, iCO-007 as monotherapy or in combination with Ranibizumab or laser for the treatment of diabetic macular edema.
  • READ3: Phase III, Ranibizumab for the treatment of diabetic macular edema with high dose.
  • RIDE: Phase III, Ranibizumab injections in subjects with clinically significant macular edema secondary to diabetes.
Retinal Vein Occlusion
  • COPERNICUS: Phase III, VEGF-Trap injections in subjects with macular edema secondary to central retinal vein occlusion.
  • HORIZON: Phase III, Ranibizumab injections in subjects with macular edema secondary to branch retinal and central retinal vein occlusion.
  • SCORE: Phase III, Ranibizumab injections in subjects with macular edema following either branch retinal vein occlusion, central retinal vein occlusion or hemi retinal vein occlusion.
  • BRAVO: Phase III, Ranibizumab injections in subjects with macular edema secondary to branch retinal vein occlusion.
  • CRUISE: Phase III, Ranibizumab injections in subjects with macular edema secondary to central retinal vein occlusion.

Complete Patient Forms

Download Form

Referring Physician Form

Download Form